ProQR Posts Q3 2026 Loss of €12.4M, Cash of €103M Funds Runway Into Mid-2028
PRQR is trading near its 52-week low of $1.2 (5.0% above the low).
Summary
ProQR reported a Q3 2026 net loss of €12.4 million and ended the quarter with €103.0 million in cash, which it says funds operations into mid-2028. The company also confirmed AX-0811 Phase 1 enrollment and set out data readouts for December 2026 and early 2027.
Key Events · Earnings and Guidance · PRQR
-
Q3 2026 Results Reported
Net loss of €12.4 million, or €0.09 per diluted share, versus €11.0 million (€0.10) in the same quarter of 2025; revenue was €5.2 million against €2.9 million a year earlier.
-
Cash Runway Extended Into Mid-2028
Cash and cash equivalents stood at €103.0 million at September 30, 2026, up from €92.4 million at December 31, 2025, after the June 2026 offering; net cash used in operations was €13.6 million for the quarter.
-
AX-0811 Phase 1 Cohorts Fully Enrolled
The first two healthy-volunteer cohorts of the AX-0811 Phase 1 trial are fully enrolled, with initial target engagement data expected in early January 2027.
-
AX-0810 Full Dataset Due December 2026
The full AX-0810 Phase 1 dataset, including Cohort 3 and 12-week follow-up, plus new AX-0811 preclinical data, is slated for presentation at the Nature Conferences RNA meeting in December 2026.
Analysis · PRQR · Life Sciences
The quarter itself was financially unremarkable — the loss widened modestly to €12.4 million from €11.0 million as R&D spending climbed to €14.3 million. What matters is the balance sheet and the calendar: €103.0 million of cash at September 30, 2026 is stated to fund operations into mid-2028, removing any near-term financing overhang for a company trading near its 52-week low. Against that backdrop, management laid out a dense catalyst schedule — full AX-0810 Phase 1 data including Cohort 3 in December 2026, initial AX-0811 target engagement data in early January 2027, and biliary atresia, AX-0422 and AX-2911 milestones in the first half of 2027. The stock's reaction will hinge on those readouts, not on the reported loss.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRQR was trading at $1.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $177.8M. The 52-week trading range was $1.20 to $2.49. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.